DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for cutaneous porphyria — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCutaneous porphyria maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cutaneous porphyria is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dopamine receptor D2 (DRD2) — DRD2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 8alphadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9BS9 · 2.28 Å · ligand (8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide (7LD). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1960 · 221 citations
Cutaneous Porphyria in Turkey
AbstractSCATTERED reports of an outbreak of cutaneous porphyria in Turkey have been received recently. In the course of a short visit to that country in January, 1960, an attempt was made to gather all available information and to supplement it with some personal observations and investigations.Since the summer of 1956 a great number of cases of cutaneous porphyria have appeared in the Turkish provinces of Diyarbakir, Mardin and Urfa. A few isolated cases had already been observed in Urfa in 1955, but before that date, porphyria had not been noted in Turkey. The syndrome consists of blistering and epidermolysis . . .
AbstractSummaryThe authors relate their experience of 36 cases of porphyria : 14 cases of acute intermittent porphyria, 4 cases of mixed porphyria and 18 cases of pure cutaneous porphyria. They review the main clinical, biochemical and biological characteristics of these groups of patients. The factors inducing porphyria and the evolution of the disease are also discussed. Two unusual forms of porphyria are presented in the group of pure cutaneous porphyria : a melanodermic form and a sclerodermic form with mutilations. Reflections on the biochemical diagnosis of the different forms of porphyrias, on the main causes of error in the detection of porphobilinogen by the Watson-Schwartz reaction and a survey of the different possibilities of therapy end this review of clinical cases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
